A. Kermani, R. Vakili, Samaneh Dadkhah, A. Jafarian, R. Bagheri
{"title":"HER-2/neu在食管鳞状细胞癌(ESCC)中的过表达及其与患者临床病理特征的相关性","authors":"A. Kermani, R. Vakili, Samaneh Dadkhah, A. Jafarian, R. Bagheri","doi":"10.17795/IJCP-5007","DOIUrl":null,"url":null,"abstract":"Background: HER-2/neu overexpression has been reported in various human cancers and identified as a significant predictor of poor survival. In this studyHER-2/neu overexpression and its associations with clinicopathological characteristics were evaluated in patients with esophageal squamous cell carcinoma (ESCC). Methods: This cross-sectional study was performed on 64 patients with histological diagnosis of primary ESCC who underwent surgery for curative treatment. Immunohistochemistry (IHC) was used to assess expression of HER-2/neu receptor in formalin-fixed paran-embedded tissue blocks. Results: The mean age of patients was 60.1 1.28 years. The overall HER2 expression was observed in 51.5% of ESCC patients without considering IHC scores. HER2/neu overexpression (6%) was significantly associated with the tumor dierentiation (P < 0.001). 20.3% of cases were stage I, 67.2% stage II, and 12.5% stage III. 17 patients (26.2%) had vascular invasion, 12 patients (18.8%) had neuronal invasion and 7 patients (10.9%) had invasion to margins. Nine of 12 patients withHER-2/neu over expression had thoracic tumors and only three of them had an abdominal ESCC. Conclusions: No significant correlations were found between HER2/neu overexpression and gender, age, tumor invasion, location of tumor, TNM stages and stage of tumor in patients with ESCC.","PeriodicalId":73510,"journal":{"name":"Iranian journal of cancer prevention","volume":"9 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2016-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"HER-2/neu Overxpression in Esophageal Squamous Cell Carcinoma (ESCC) and Its Correlation with Patient’s Clinicopathological Features\",\"authors\":\"A. Kermani, R. Vakili, Samaneh Dadkhah, A. Jafarian, R. Bagheri\",\"doi\":\"10.17795/IJCP-5007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: HER-2/neu overexpression has been reported in various human cancers and identified as a significant predictor of poor survival. In this studyHER-2/neu overexpression and its associations with clinicopathological characteristics were evaluated in patients with esophageal squamous cell carcinoma (ESCC). Methods: This cross-sectional study was performed on 64 patients with histological diagnosis of primary ESCC who underwent surgery for curative treatment. Immunohistochemistry (IHC) was used to assess expression of HER-2/neu receptor in formalin-fixed paran-embedded tissue blocks. Results: The mean age of patients was 60.1 1.28 years. The overall HER2 expression was observed in 51.5% of ESCC patients without considering IHC scores. HER2/neu overexpression (6%) was significantly associated with the tumor dierentiation (P < 0.001). 20.3% of cases were stage I, 67.2% stage II, and 12.5% stage III. 17 patients (26.2%) had vascular invasion, 12 patients (18.8%) had neuronal invasion and 7 patients (10.9%) had invasion to margins. Nine of 12 patients withHER-2/neu over expression had thoracic tumors and only three of them had an abdominal ESCC. Conclusions: No significant correlations were found between HER2/neu overexpression and gender, age, tumor invasion, location of tumor, TNM stages and stage of tumor in patients with ESCC.\",\"PeriodicalId\":73510,\"journal\":{\"name\":\"Iranian journal of cancer prevention\",\"volume\":\"9 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-09-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Iranian journal of cancer prevention\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17795/IJCP-5007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian journal of cancer prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17795/IJCP-5007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
HER-2/neu Overxpression in Esophageal Squamous Cell Carcinoma (ESCC) and Its Correlation with Patient’s Clinicopathological Features
Background: HER-2/neu overexpression has been reported in various human cancers and identified as a significant predictor of poor survival. In this studyHER-2/neu overexpression and its associations with clinicopathological characteristics were evaluated in patients with esophageal squamous cell carcinoma (ESCC). Methods: This cross-sectional study was performed on 64 patients with histological diagnosis of primary ESCC who underwent surgery for curative treatment. Immunohistochemistry (IHC) was used to assess expression of HER-2/neu receptor in formalin-fixed paran-embedded tissue blocks. Results: The mean age of patients was 60.1 1.28 years. The overall HER2 expression was observed in 51.5% of ESCC patients without considering IHC scores. HER2/neu overexpression (6%) was significantly associated with the tumor dierentiation (P < 0.001). 20.3% of cases were stage I, 67.2% stage II, and 12.5% stage III. 17 patients (26.2%) had vascular invasion, 12 patients (18.8%) had neuronal invasion and 7 patients (10.9%) had invasion to margins. Nine of 12 patients withHER-2/neu over expression had thoracic tumors and only three of them had an abdominal ESCC. Conclusions: No significant correlations were found between HER2/neu overexpression and gender, age, tumor invasion, location of tumor, TNM stages and stage of tumor in patients with ESCC.